Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel and bio-therapeutic solutions for tissue repair and regeneration. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was founded in 2000 and is headquartered in Yavne, Israel.

MediWound Ltd.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

MEDIWOUND ANNOUNCES $30 MILLION REGISTERED DIRECT OFFERING OF ORDINARY SHARES

MEDIWOUND EXPANDS GLOBAL REACH WITH MARKETING APPROVAL OF NEXOBRID  IN AUSTRALIA

MEDIWOUND EXPANDS GLOBAL REACH WITH MARKETING APPROVAL OF NEXOBRID IN AUSTRALIA

MEDIWOUND'S NEXOBRID  TO BE HIGHLIGHTED IN 36 SCIENTIFIC PRESENTATIONS AT THE 21ST EUROPEAN BURNS ASSOCIATION CONGRESS YAVNE, ISRAEL, SEPTEMBER 2, 2025 -- MEDIWOUND LTD. (NASDAQ: MDWD), A GLOBAL LEADER IN NEXT-GENERATION ENZYMATIC THERAPEUTICS FOR TISSUE REPAIR, TODAY ANNOUNCED ITS PARTICIPATION AT THE 21ST EUROPEAN BURNS ASSOCIATION (EBA) CONGRESS, TAKING PLACE SEPTEMBER 3-6, 2025, IN BERLIN, GERMANY.

MEDIWOUND'S NEXOBRID TO BE HIGHLIGHTED IN 36 SCIENTIFIC PRESENTATIONS AT THE 21ST EUROPEAN BURNS ASSOCIATION CONGRESS

YAVNE, ISRAEL, AUGUST 20, 2025 -- MEDIWOUND LTD. (NASDAQ: MDWD), A GLOBAL LEADER IN NEXT-GENERATION ENZYMATIC THERAPEUTICS FOR TISSUE REPAIR, TODAY ANNOUNCED THAT OFER GONEN, CHIEF EXECUTIVE OFFICER, WILL PARTICIPATE IN A FIRESIDE CHAT, HOSTED BY SWAYAMPAKULA RAMAKANTH, MANAGING DIRECTOR, SENIOR EQUITY RESEARCH ANALYST, ON MONDAY, SEPTEMBER 8, 2025 AT 4:30P.M. ET AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE.

MEDIWOUND TO PRESENT AT THE H.C. WAINWRIGHT 27TH ANNUAL GLOBAL INVESTMENT CONFERENCE

VALUE PHASE III TRIAL OF ESCHAREX  IN VENOUS LEG ULCERS CONTINUES TO ENROLL PATIENTS NEXOBRID  MANUFACTURING EXPANSION ON TRACK; FULL OPERATIONAL CAPACITY EXPECTED BY YEAR-END 2025 ADDITIONAL STRATEGIC RESEARCH COLLABORATIONS ESTABLISHED WITH ESSITY AND CONVATEC SECOND QUARTER 2025 REVENUE OF $5.7 MILLION, UP 43% FROM PRIOR QUARTER CONFERENCE CALL TODAY, AUGUST 14, 2025, AT 8:30AM EASTERN TIME YAVNE, ISRAEL, AUG. 14, 2025 (GLOBE NEWSWIRE) -- MEDIWOUND LTD. (NASDAQ: MDWD), A GLOBAL LEADER IN NEXT-GENERATION ENZYMATIC THERAPEUTICS FOR TISSUE REPAIR, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDED JUNE 30, 2025, AND PROVIDED A CORPORATE UPDATE.

MEDIWOUND REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

MEDIWOUND ANNOUNCES NEW ESCHAREX  PHASE II DATA DEMONSTRATING STRONG LINK BETWEEN WOUND BED PREPARATION AND WOUND CLOSURE IN VENOUS LEG ULCERS

MEDIWOUND ANNOUNCES NEW ESCHAREX PHASE II DATA DEMONSTRATING STRONG LINK BETWEEN WOUND BED PREPARATION AND WOUND CLOSURE IN VENOUS LEG ULCERS

MEDIWOUND TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS CONFERENCE CALL AND WEBCAST SCHEDULED FOR THURSDAY, AUGUST 14 AT 8:30 A.M. EASTERN TIME YAVNE, ISRAEL, AUGUST 4, 2025 -- MEDIWOUND LTD.

MEDIWOUND TO REPORT SECOND QUARTER 2025 FINANCIAL RESULTS

VALUE PHASE III TRIAL OF ESCHAREX  IN VENOUS LEG ULCERS ADVANCING AS PLANNED NEXOBRID  MANUFACTURING EXPANSION ON TRACK; FULL OPERATIONAL CAPACITY EXPECTED BY YEAR-END 2025 FIRST QUARTER REVENUE OF $4 MILLION; FULL-YEAR 2025 REVENUE GUIDANCE REAFFIRMED AT $24 MILLION CONFERENCE CALL TODAY, MAY 21 AT 8:30AM EASTERN TIME YAVNE, ISRAEL, MAY 21, 2025 (GLOBE NEWSWIRE) -- MEDIWOUND LTD. (NASDAQ: MDWD), A GLOBAL LEADER IN NEXT-GENERATION ENZYMATIC THERAPEUTICS FOR TISSUE REPAIR, TODAY ANNOUNCED FINANCIAL RESULTS FOR THE FIRST QUARTER ENDED MARCH 31, 2025, AND PROVIDED A CORPORATE UPDATE.

MEDIWOUND REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

POST HOC ANALYSIS PUBLISHED IN THE PEER-REVIEWED JOURNAL WOUNDS HIGHLIGHTS ESCHAREX'S SUPERIOR CLINICAL PERFORMANCE AND COMPARABLE SAFETY PROFILE TO SANTYL POST HOC ANALYSIS PUBLISHED IN THE PEER-REVIEWED JOURNAL WOUNDS HIGHLIGHTS ESCHAREX'S SUPERIOR CLINICAL PERFORMANCE AND COMPARABLE SAFETY PROFILE TO SANTYL

MEDIWOUND ANNOUNCES PUBLICATION OF PHASE II ESCHAREX DATA DEMONSTRATING SUPERIORITY OVER COLLAGENASE IN VENOUS LEG ULCERS

CONFERENCE CALL AND WEBCAST SCHEDULED FOR WEDNESDAY, MAY 21, 2025, AT 8:30 A.M. EASTERN TIME CONFERENCE CALL AND WEBCAST SCHEDULED FOR WEDNESDAY, MAY 21, 2025, AT 8:30 A.M. EASTERN TIME

MediWound Ltd.

MDWD

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MediWound Ltd.

MDWD.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

MDWD